arrow
S

Shelya X. Zeng

Tulane University School of Medicine
H指数:28
被引数:2,780

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Increased therapeutic index of muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with pembrolizumab (pembro) enables significant clinical benefits and supports further clinical development in patients with metastatic MSS CRC

未修饰的抗-CTLA-4抗体muzastotug(ADG126)与pembrolizumab(pembro)联合应用,其治疗指数的增加可实现显著的临床获益,并支持其在转移性MSS结直肠癌患者中进一步的临床开发。

2024-09-010
PRE
The Mettl3 epitranscriptomic writer amplifies p53 stress responses
2022-07-0137
OA